计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| R172598-5mg |
5mg |
现货 ![]() |
| |
| R172598-10mg |
10mg |
现货 ![]() |
| |
| R172598-25mg |
25mg |
现货 ![]() |
| |
| R172598-50mg |
50mg |
现货 ![]() |
| |
| R172598-100mg |
100mg |
现货 ![]() |
| |
| R172598-250mg |
250mg |
现货 ![]() |
| |
| R172598-1g |
1g |
现货 ![]() |
|
| 别名 | 瑞博西林 |
|---|---|
| 英文别名 | Cambridge id 5121815 | DB11730 | Q27088552 | AC-30029 | Ribociclib [INN] | 6ZZ | BCP08804 | SW220101-1 | FT-0700117 | TK8ERE8P56 | HY-15777 | 7-Cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide | B |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Ribociclib |
| 生化机理 | 双重cdk4 / cdk6抑制剂。诱导神经母细胞瘤细胞系(IC50 = 306 nM)的G1期细胞周期停滞和衰老。延迟体内肿瘤生长。口服具有生物活性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 细胞周期蛋白依赖性激酶 6 抑制剂 |
| 产品介绍 |
Ribociclib (LEE011) 是一种 高度特异性的CDK4和CDK6抑制剂,对应的IC50值分别为10 nM和39 nM。Phase 3。 LEE011(NVP-LEE011)是高度特异性的CDK4/CDK6抑制剂,通过减少磷酸化的RB和FOXM1来发挥作用。在17种人神经母细胞瘤细胞系中, 12种对LEE011敏感,平均IC50值为306±68 nM。 CDK4/6可通过磷酸化肿瘤抑制蛋白RB来增加G1-S期细胞周期的进程,从而诱导细胞增殖。CDK4/6信号也可以通过调节FOXM1转录来抑制衰老[3]。大量研究表明,CDK4/CDK6的过表达与肿瘤发生和疾病进展相关。 LEE011是一种新型的CDK4/CDK6抑制剂。在人脂肪肉瘤细胞系中,LEE011可通过阻滞G0-G1细胞周期,显著抑制细胞生长。在12/17种人神经母细胞瘤来源的细胞系中,LEE011处理后可显著减少细胞增殖。 在异种移植人脂肪肉瘤的小鼠模型中,LEE011持续口服治疗后可以抑制肿瘤生长或诱导肿瘤衰退,而对小鼠的体重没有产生不利影响。在异种移植神经母细胞瘤细胞的小鼠中,LEE011治疗可抑制肿瘤生长。 |
| 纯度 | ≥98% |
| ALogP | 2.2 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488201076 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide |
| INCHI | 1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28) |
| InChi Key | RHXHGRAEPCAFML-UHFFFAOYSA-N |
| Smiles | CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5 |
| Isomeric SMILES | CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5 |
| 分子量 | 434.5 |
| Reaxy-Rn | 20117577 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=20117577&ln= |
| 溶解性 | 溶于DMSO, 最高浓度 (mg/mL): 4.35, 最高浓度(mM): 10 |
|---|---|
| 分子量 | 434.500 g/mol |
| XLogP3 | 2.200 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 434.254 Da |
| 单同位素质量Monoisotopic Mass | 434.254 Da |
| 拓扑极表面积Topological Polar Surface Area | 91.200 Ų |
| 重原子数Heavy Atom Count | 32 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 635.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 | |
| 分析证书 | R172598 |
| 1. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M et al.. (2010) The landscape of somatic copy-number alteration across human cancers.. Nature, 463 (7283): (899-905). [PMID:20164920] |
| 2. Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, Guerra C, Santamaría D, Barbacid M. (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.. Cancer Cell, 18 (1): (63-73). [PMID:20609353] |
| 3. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES. (2012) Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.. Cell Cycle, 11 (14): (2756-61). [PMID:22767154] |
| 4. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H et al.. (2012) The requirement for cyclin D function in tumor maintenance.. Cancer Cell, 22 (4): (438-51). [PMID:23079655] |
| 5. Sawai CM, Freund J, Oh P, Ndiaye-Lobry D, Bretz JC, Strikoudis A, Genesca L, Trimarchi T, Kelliher MA, Clark M et al.. (2012) Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.. Cancer Cell, 22 (4): (452-65). [PMID:23079656] |
| 6. Zhang XH, Cheng Y, Shin JY, Kim JO, Oh JE, Kang JH. (2013) A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.. Cancer Biol Ther, 14 (7): (597-605). [PMID:23792647] |
| 7. Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ et al.. (2013) Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.. Clin Cancer Res, 19 (22): (6173-82). [PMID:24045179] |
| 8. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP et al.. (2016) Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.. N Engl J Med, 375 (18): (1738-1748). [PMID:27717303] |
| 9. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS et al.. (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.. Lancet Oncol, 19 (7): (904-915). [PMID:29804902] |
| 10. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.. Biochim Biophys Acta, 1812 (8): (982-94). [PMID:21193033] |